$GRAL
GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.
Healthcare
Sector
Medical - Diagnostics & Research
Industry
Robert Ragusa
CEO
1000
Employees
$117.81
Current Price
$3.77B
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 1 month | Buys | 0 | 0 | - | - | All Sells |
| Sells | 3 | 8 | $7,347,058.59 | 51,492 | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 3 | 19 | $13,736,116.10 | 117,044 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 3 | 21 | $14,832,793.10 | 129,944 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Aug 27, 2026 | Freidin Aaron Chief Financial Officer | Sale | 7,900 | $85.01 | $671,579.00 | View Details |
27 more transactions available โ create a free account to see 12 months of history | ||||||
Showing 21โ21 of 21 transactions
Upcoming Earnings
Scheduled earnings reports
EPS
Estimated-$2.45
ActualN/A
Revenue
Estimated$44.21M
ActualN/A
Past Earnings
Historical earnings results
No earnings data in the last 3 months. Sign up free to see 12 months of history.